Global Injectable HIV Medication Market Growth 2026-2032
The global Injectable HIV Medication market size is predicted to grow from US$ 299 million in 2025 to US$ 827 million in 2032; it is expected to grow at a CAGR of 15.8% from 2026 to 2032.
Injectable HIV medication refers to antiretroviral drugs formulated for administration by injection—most commonly intramuscular or subcutaneous—to treat HIV infection (ART) and, in some cases, to prevent infection (e.g., PrEP) by achieving rapid therapeutic exposure or maintaining effective drug levels over a defined period. These products are intended to mitigate real-world limitations of daily oral therapy, including missed doses, pill fatigue, privacy and stigma pressures, gastrointestinal tolerability issues, and regimen complexity in patients with comorbidities; when supported by structured clinical follow-up, injection-based administration can reduce day-to-day adherence burden and improve continuity of care. Historically, HIV management began with predominantly oral combination regimens, and as efficacy and safety profiles improved over successive generations, innovation increasingly shifted toward delivery convenience and adherence in real-world settings; injectable options evolved from shorter-acting parenteral approaches used in specific clinical contexts to longer-maintenance injectable formulations, positioning injection-based therapy as a key adherence-focused modality. The upstream supply chain typically covers APIs and key intermediates (specialty chemicals, chiral building blocks, solvents, catalysts), injection-grade excipients (buffers, tonicity agents, stabilizers, surfactants, solubilizers, preservatives or preservative-free single-dose systems, and, for depot/extended-release forms, polymer or lipid carriers), sterile disposables and packaging (syringes and needles, prefilled systems, glass vials or high-barrier polymer containers, rubber stoppers and seals, sterile filtration membranes, aseptic connectors and single-use tubing), as well as critical manufacturing and QC “components” (metering pumps and valve assemblies for aseptic filling lines, isolator or laminar-flow filtration elements, in-line pressure/flow/temperature sensors, particle-size and fill-inspection modules, and cold-chain monitoring devices). Because injectables impose stricter requirements on sterility assurance, extractables/leachables control, particulate/visible matter, and storage stability, upstream pharmaceutical-grade material quality and supply robustness are often decisive for scalable commercialization.In 2025, global production capacity for injectable HIV medications reached 150,000 doses, while sales amounted to 131,000 doses. The average selling price was approximately USD 2,325 per dose, and gross margins across manufacturers were in the range of 60%–70%.
In today’s market, injectable HIV medications are expanding from limited use in specialized centers toward broader, stratified adoption, with real-world success increasingly determined by “drug plus service delivery” rather than pharmacology alone. In treatment settings, clinicians tend to position injectable options for patients with higher adherence risk, suboptimal stability on daily oral regimens, or strong preferences for reducing the visibility of daily dosing; in prevention settings, injectables integrate naturally with sexual health clinics, community programs, and public health pathways that can support scheduled follow-up and continuity. Operationally, the commercial focus has shifted toward workflow and experience management—reliable appointment cadence, accessible administration sites, cold-chain and inventory turnover, and standardized handling of adverse events—while regional variation is largely driven by differences in healthcare density, clinic-level injection capacity, reimbursement and access rules, and the broader privacy and stigma environment.
Looking forward, the trajectory points to longer dosing intervals, smaller injection volumes, improved local tolerability, more stable exposure profiles, stronger resistance barriers, and reduced healthcare burden, enabled by both platform innovation and new care models. On the formulation side, developers will continue refining depot delivery systems and stability profiles to ease cold-chain constraints and improve transport and storage flexibility, alongside more user-friendly administration formats such as optimized prefilled devices and standardized administration kits. On the regimen side, greater emphasis will be placed on switchability and durable maintenance strategies that remain resilient to missed visits or delays. On the delivery side, more “decentralized administration” is likely—extending dosing beyond large hospitals to community clinics, partnered pharmacy sites, or mobile care teams—paired with telehealth follow-up and digital scheduling/adherence tools so patients can sustain protection or suppression with fewer high-friction touchpoints. In parallel, pathways for testing, resistance assessment, switching, and contingency planning are expected to become more standardized, improving scalability and consistency.
Growth drivers and constraints will continue to coexist. Adoption is propelled by public health priorities to reduce interruptions and onward transmission, patient demand for quality of life and discretion, and clinical urgency to improve real-world adherence; industry momentum is supported by maturing sterile manufacturing, device-enabled administration, and cold-chain infrastructure, as well as payer interest in outcome-oriented management. However, barriers remain substantial: injectable administration depends on healthcare networks, creating pronounced geographic access disparities; cold-chain, inventory, and scheduling introduce operational load for lower-resourced sites; injection-site reactions and long-term tolerability require training and standardization; interruption or delayed visits can create vulnerability during a pharmacokinetic “tail,” necessitating disciplined follow-up and mitigation strategies. Social factors—stigma, information gaps, needle aversion, and the inconvenience of repeated clinic visits—can also reduce persistence. As a result, competitive advantage will increasingly come from delivering a low-friction, scalable end-to-end system across screening, administration, follow-up, supply assurance, and risk management, not just from the molecule itself.
LP Information, Inc. (LPI) ' newest research report, the “Injectable HIV Medication Industry Forecast” looks at past sales and reviews total world Injectable HIV Medication sales in 2025, providing a comprehensive analysis by region and market sector of projected Injectable HIV Medication sales for 2026 through 2032. With Injectable HIV Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Injectable HIV Medication industry.
This Insight Report provides a comprehensive analysis of the global Injectable HIV Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Injectable HIV Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Injectable HIV Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Injectable HIV Medication and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Injectable HIV Medication.
This report presents a comprehensive overview, market shares, and growth opportunities of Injectable HIV Medication market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Injectable HIV Medication market?
What factors are driving Injectable HIV Medication market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Injectable HIV Medication market opportunities vary by end market size?
How does Injectable HIV Medication break out by Type, by Application?
Injectable HIV medication refers to antiretroviral drugs formulated for administration by injection—most commonly intramuscular or subcutaneous—to treat HIV infection (ART) and, in some cases, to prevent infection (e.g., PrEP) by achieving rapid therapeutic exposure or maintaining effective drug levels over a defined period. These products are intended to mitigate real-world limitations of daily oral therapy, including missed doses, pill fatigue, privacy and stigma pressures, gastrointestinal tolerability issues, and regimen complexity in patients with comorbidities; when supported by structured clinical follow-up, injection-based administration can reduce day-to-day adherence burden and improve continuity of care. Historically, HIV management began with predominantly oral combination regimens, and as efficacy and safety profiles improved over successive generations, innovation increasingly shifted toward delivery convenience and adherence in real-world settings; injectable options evolved from shorter-acting parenteral approaches used in specific clinical contexts to longer-maintenance injectable formulations, positioning injection-based therapy as a key adherence-focused modality. The upstream supply chain typically covers APIs and key intermediates (specialty chemicals, chiral building blocks, solvents, catalysts), injection-grade excipients (buffers, tonicity agents, stabilizers, surfactants, solubilizers, preservatives or preservative-free single-dose systems, and, for depot/extended-release forms, polymer or lipid carriers), sterile disposables and packaging (syringes and needles, prefilled systems, glass vials or high-barrier polymer containers, rubber stoppers and seals, sterile filtration membranes, aseptic connectors and single-use tubing), as well as critical manufacturing and QC “components” (metering pumps and valve assemblies for aseptic filling lines, isolator or laminar-flow filtration elements, in-line pressure/flow/temperature sensors, particle-size and fill-inspection modules, and cold-chain monitoring devices). Because injectables impose stricter requirements on sterility assurance, extractables/leachables control, particulate/visible matter, and storage stability, upstream pharmaceutical-grade material quality and supply robustness are often decisive for scalable commercialization.In 2025, global production capacity for injectable HIV medications reached 150,000 doses, while sales amounted to 131,000 doses. The average selling price was approximately USD 2,325 per dose, and gross margins across manufacturers were in the range of 60%–70%.
In today’s market, injectable HIV medications are expanding from limited use in specialized centers toward broader, stratified adoption, with real-world success increasingly determined by “drug plus service delivery” rather than pharmacology alone. In treatment settings, clinicians tend to position injectable options for patients with higher adherence risk, suboptimal stability on daily oral regimens, or strong preferences for reducing the visibility of daily dosing; in prevention settings, injectables integrate naturally with sexual health clinics, community programs, and public health pathways that can support scheduled follow-up and continuity. Operationally, the commercial focus has shifted toward workflow and experience management—reliable appointment cadence, accessible administration sites, cold-chain and inventory turnover, and standardized handling of adverse events—while regional variation is largely driven by differences in healthcare density, clinic-level injection capacity, reimbursement and access rules, and the broader privacy and stigma environment.
Looking forward, the trajectory points to longer dosing intervals, smaller injection volumes, improved local tolerability, more stable exposure profiles, stronger resistance barriers, and reduced healthcare burden, enabled by both platform innovation and new care models. On the formulation side, developers will continue refining depot delivery systems and stability profiles to ease cold-chain constraints and improve transport and storage flexibility, alongside more user-friendly administration formats such as optimized prefilled devices and standardized administration kits. On the regimen side, greater emphasis will be placed on switchability and durable maintenance strategies that remain resilient to missed visits or delays. On the delivery side, more “decentralized administration” is likely—extending dosing beyond large hospitals to community clinics, partnered pharmacy sites, or mobile care teams—paired with telehealth follow-up and digital scheduling/adherence tools so patients can sustain protection or suppression with fewer high-friction touchpoints. In parallel, pathways for testing, resistance assessment, switching, and contingency planning are expected to become more standardized, improving scalability and consistency.
Growth drivers and constraints will continue to coexist. Adoption is propelled by public health priorities to reduce interruptions and onward transmission, patient demand for quality of life and discretion, and clinical urgency to improve real-world adherence; industry momentum is supported by maturing sterile manufacturing, device-enabled administration, and cold-chain infrastructure, as well as payer interest in outcome-oriented management. However, barriers remain substantial: injectable administration depends on healthcare networks, creating pronounced geographic access disparities; cold-chain, inventory, and scheduling introduce operational load for lower-resourced sites; injection-site reactions and long-term tolerability require training and standardization; interruption or delayed visits can create vulnerability during a pharmacokinetic “tail,” necessitating disciplined follow-up and mitigation strategies. Social factors—stigma, information gaps, needle aversion, and the inconvenience of repeated clinic visits—can also reduce persistence. As a result, competitive advantage will increasingly come from delivering a low-friction, scalable end-to-end system across screening, administration, follow-up, supply assurance, and risk management, not just from the molecule itself.
LP Information, Inc. (LPI) ' newest research report, the “Injectable HIV Medication Industry Forecast” looks at past sales and reviews total world Injectable HIV Medication sales in 2025, providing a comprehensive analysis by region and market sector of projected Injectable HIV Medication sales for 2026 through 2032. With Injectable HIV Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Injectable HIV Medication industry.
This Insight Report provides a comprehensive analysis of the global Injectable HIV Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Injectable HIV Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Injectable HIV Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Injectable HIV Medication and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Injectable HIV Medication.
This report presents a comprehensive overview, market shares, and growth opportunities of Injectable HIV Medication market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- NNRTIs
- Capsid Inhibitors
- Integrase Inhibitors
- Monoclonal Antibodies
- Other
- Short-interval Injections
- Monthly Injections
- Quarterly Injections
- Original Drug
- Generic Drug
- Pre-Exposure Prophylaxis
- HIV Treatment
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- ViiV Healthcare
- Janssen Pharmaceuticals
- Gilead Sciences
- Theratechnologies
What is the 10-year outlook for the global Injectable HIV Medication market?
What factors are driving Injectable HIV Medication market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Injectable HIV Medication market opportunities vary by end market size?
How does Injectable HIV Medication break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Injectable HIV Medication Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Injectable HIV Medication by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Injectable HIV Medication by Country/Region, 2021, 2025 & 2032
2.2 Injectable HIV Medication Segment by Type
2.2.1 NNRTIs
2.2.2 Capsid Inhibitors
2.2.3 Integrase Inhibitors
2.2.4 Monoclonal Antibodies
2.2.5 Other
2.2.6 Injectable HIV Medication Sales by Type
2.2.6.1 Global Injectable HIV Medication Sales Market Share by Type (2021-2026)
2.2.6.2 Global Injectable HIV Medication Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Injectable HIV Medication Sale Price by Type (2021-2026)
2.3 Injectable HIV Medication Segment by Dosing Interval
2.3.1 Short-interval Injections
2.3.2 Monthly Injections
2.3.3 Quarterly Injections
2.3.4 Injectable HIV Medication Sales by Dosing Interval
2.3.4.1 Global Injectable HIV Medication Sales Market Share by Dosing Interval (2021-2026)
2.3.4.2 Global Injectable HIV Medication Revenue and Market Share by Dosing Interval (2021-2026)
2.3.4.3 Global Injectable HIV Medication Sale Price by Dosing Interval (2021-2026)
2.4 Injectable HIV Medication Segment by Drug Properties
2.4.1 Original Drug
2.4.2 Generic Drug
2.4.3 Injectable HIV Medication Sales by Drug Properties
2.4.3.1 Global Injectable HIV Medication Sales Market Share by Drug Properties (2021-2026)
2.4.3.2 Global Injectable HIV Medication Revenue and Market Share by Drug Properties (2021-2026)
2.4.3.3 Global Injectable HIV Medication Sale Price by Drug Properties (2021-2026)
2.5 Injectable HIV Medication Segment by Application
2.5.1 Pre-Exposure Prophylaxis
2.5.2 HIV Treatment
2.5.3 Injectable HIV Medication Sales by Application
2.5.3.1 Global Injectable HIV Medication Sale Market Share by Application (2021-2026)
2.5.3.2 Global Injectable HIV Medication Revenue and Market Share by Application (2021-2026)
2.5.3.3 Global Injectable HIV Medication Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Injectable HIV Medication Breakdown Data by Company
3.1.1 Global Injectable HIV Medication Annual Sales by Company (2021-2026)
3.1.2 Global Injectable HIV Medication Sales Market Share by Company (2021-2026)
3.2 Global Injectable HIV Medication Annual Revenue by Company (2021-2026)
3.2.1 Global Injectable HIV Medication Revenue by Company (2021-2026)
3.2.2 Global Injectable HIV Medication Revenue Market Share by Company (2021-2026)
3.3 Global Injectable HIV Medication Sale Price by Company
3.4 Key Manufacturers Injectable HIV Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Injectable HIV Medication Product Location Distribution
3.4.2 Players Injectable HIV Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR INJECTABLE HIV MEDICATION BY GEOGRAPHIC REGION
4.1 World Historic Injectable HIV Medication Market Size by Geographic Region (2021-2026)
4.1.1 Global Injectable HIV Medication Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Injectable HIV Medication Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Injectable HIV Medication Market Size by Country/Region (2021-2026)
4.2.1 Global Injectable HIV Medication Annual Sales by Country/Region (2021-2026)
4.2.2 Global Injectable HIV Medication Annual Revenue by Country/Region (2021-2026)
4.3 Americas Injectable HIV Medication Sales Growth
4.4 APAC Injectable HIV Medication Sales Growth
4.5 Europe Injectable HIV Medication Sales Growth
4.6 Middle East & Africa Injectable HIV Medication Sales Growth
5 AMERICAS
5.1 Americas Injectable HIV Medication Sales by Country
5.1.1 Americas Injectable HIV Medication Sales by Country (2021-2026)
5.1.2 Americas Injectable HIV Medication Revenue by Country (2021-2026)
5.2 Americas Injectable HIV Medication Sales by Type (2021-2026)
5.3 Americas Injectable HIV Medication Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Injectable HIV Medication Sales by Region
6.1.1 APAC Injectable HIV Medication Sales by Region (2021-2026)
6.1.2 APAC Injectable HIV Medication Revenue by Region (2021-2026)
6.2 APAC Injectable HIV Medication Sales by Type (2021-2026)
6.3 APAC Injectable HIV Medication Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Injectable HIV Medication by Country
7.1.1 Europe Injectable HIV Medication Sales by Country (2021-2026)
7.1.2 Europe Injectable HIV Medication Revenue by Country (2021-2026)
7.2 Europe Injectable HIV Medication Sales by Type (2021-2026)
7.3 Europe Injectable HIV Medication Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Injectable HIV Medication by Country
8.1.1 Middle East & Africa Injectable HIV Medication Sales by Country (2021-2026)
8.1.2 Middle East & Africa Injectable HIV Medication Revenue by Country (2021-2026)
8.2 Middle East & Africa Injectable HIV Medication Sales by Type (2021-2026)
8.3 Middle East & Africa Injectable HIV Medication Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Injectable HIV Medication
10.3 Manufacturing Process Analysis of Injectable HIV Medication
10.4 Industry Chain Structure of Injectable HIV Medication
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Injectable HIV Medication Distributors
11.3 Injectable HIV Medication Customer
12 WORLD FORECAST REVIEW FOR INJECTABLE HIV MEDICATION BY GEOGRAPHIC REGION
12.1 Global Injectable HIV Medication Market Size Forecast by Region
12.1.1 Global Injectable HIV Medication Forecast by Region (2027-2032)
12.1.2 Global Injectable HIV Medication Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Injectable HIV Medication Forecast by Type (2027-2032)
12.7 Global Injectable HIV Medication Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ViiV Healthcare
13.1.1 ViiV Healthcare Company Information
13.1.2 ViiV Healthcare Injectable HIV Medication Product Portfolios and Specifications
13.1.3 ViiV Healthcare Injectable HIV Medication Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ViiV Healthcare Main Business Overview
13.1.5 ViiV Healthcare Latest Developments
13.2 Janssen Pharmaceuticals
13.2.1 Janssen Pharmaceuticals Company Information
13.2.2 Janssen Pharmaceuticals Injectable HIV Medication Product Portfolios and Specifications
13.2.3 Janssen Pharmaceuticals Injectable HIV Medication Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Janssen Pharmaceuticals Main Business Overview
13.2.5 Janssen Pharmaceuticals Latest Developments
13.3 Gilead Sciences
13.3.1 Gilead Sciences Company Information
13.3.2 Gilead Sciences Injectable HIV Medication Product Portfolios and Specifications
13.3.3 Gilead Sciences Injectable HIV Medication Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Gilead Sciences Main Business Overview
13.3.5 Gilead Sciences Latest Developments
13.4 Theratechnologies
13.4.1 Theratechnologies Company Information
13.4.2 Theratechnologies Injectable HIV Medication Product Portfolios and Specifications
13.4.3 Theratechnologies Injectable HIV Medication Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Theratechnologies Main Business Overview
13.4.5 Theratechnologies Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Injectable HIV Medication Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Injectable HIV Medication by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Injectable HIV Medication by Country/Region, 2021, 2025 & 2032
2.2 Injectable HIV Medication Segment by Type
2.2.1 NNRTIs
2.2.2 Capsid Inhibitors
2.2.3 Integrase Inhibitors
2.2.4 Monoclonal Antibodies
2.2.5 Other
2.2.6 Injectable HIV Medication Sales by Type
2.2.6.1 Global Injectable HIV Medication Sales Market Share by Type (2021-2026)
2.2.6.2 Global Injectable HIV Medication Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Injectable HIV Medication Sale Price by Type (2021-2026)
2.3 Injectable HIV Medication Segment by Dosing Interval
2.3.1 Short-interval Injections
2.3.2 Monthly Injections
2.3.3 Quarterly Injections
2.3.4 Injectable HIV Medication Sales by Dosing Interval
2.3.4.1 Global Injectable HIV Medication Sales Market Share by Dosing Interval (2021-2026)
2.3.4.2 Global Injectable HIV Medication Revenue and Market Share by Dosing Interval (2021-2026)
2.3.4.3 Global Injectable HIV Medication Sale Price by Dosing Interval (2021-2026)
2.4 Injectable HIV Medication Segment by Drug Properties
2.4.1 Original Drug
2.4.2 Generic Drug
2.4.3 Injectable HIV Medication Sales by Drug Properties
2.4.3.1 Global Injectable HIV Medication Sales Market Share by Drug Properties (2021-2026)
2.4.3.2 Global Injectable HIV Medication Revenue and Market Share by Drug Properties (2021-2026)
2.4.3.3 Global Injectable HIV Medication Sale Price by Drug Properties (2021-2026)
2.5 Injectable HIV Medication Segment by Application
2.5.1 Pre-Exposure Prophylaxis
2.5.2 HIV Treatment
2.5.3 Injectable HIV Medication Sales by Application
2.5.3.1 Global Injectable HIV Medication Sale Market Share by Application (2021-2026)
2.5.3.2 Global Injectable HIV Medication Revenue and Market Share by Application (2021-2026)
2.5.3.3 Global Injectable HIV Medication Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Injectable HIV Medication Breakdown Data by Company
3.1.1 Global Injectable HIV Medication Annual Sales by Company (2021-2026)
3.1.2 Global Injectable HIV Medication Sales Market Share by Company (2021-2026)
3.2 Global Injectable HIV Medication Annual Revenue by Company (2021-2026)
3.2.1 Global Injectable HIV Medication Revenue by Company (2021-2026)
3.2.2 Global Injectable HIV Medication Revenue Market Share by Company (2021-2026)
3.3 Global Injectable HIV Medication Sale Price by Company
3.4 Key Manufacturers Injectable HIV Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Injectable HIV Medication Product Location Distribution
3.4.2 Players Injectable HIV Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR INJECTABLE HIV MEDICATION BY GEOGRAPHIC REGION
4.1 World Historic Injectable HIV Medication Market Size by Geographic Region (2021-2026)
4.1.1 Global Injectable HIV Medication Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Injectable HIV Medication Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Injectable HIV Medication Market Size by Country/Region (2021-2026)
4.2.1 Global Injectable HIV Medication Annual Sales by Country/Region (2021-2026)
4.2.2 Global Injectable HIV Medication Annual Revenue by Country/Region (2021-2026)
4.3 Americas Injectable HIV Medication Sales Growth
4.4 APAC Injectable HIV Medication Sales Growth
4.5 Europe Injectable HIV Medication Sales Growth
4.6 Middle East & Africa Injectable HIV Medication Sales Growth
5 AMERICAS
5.1 Americas Injectable HIV Medication Sales by Country
5.1.1 Americas Injectable HIV Medication Sales by Country (2021-2026)
5.1.2 Americas Injectable HIV Medication Revenue by Country (2021-2026)
5.2 Americas Injectable HIV Medication Sales by Type (2021-2026)
5.3 Americas Injectable HIV Medication Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Injectable HIV Medication Sales by Region
6.1.1 APAC Injectable HIV Medication Sales by Region (2021-2026)
6.1.2 APAC Injectable HIV Medication Revenue by Region (2021-2026)
6.2 APAC Injectable HIV Medication Sales by Type (2021-2026)
6.3 APAC Injectable HIV Medication Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Injectable HIV Medication by Country
7.1.1 Europe Injectable HIV Medication Sales by Country (2021-2026)
7.1.2 Europe Injectable HIV Medication Revenue by Country (2021-2026)
7.2 Europe Injectable HIV Medication Sales by Type (2021-2026)
7.3 Europe Injectable HIV Medication Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Injectable HIV Medication by Country
8.1.1 Middle East & Africa Injectable HIV Medication Sales by Country (2021-2026)
8.1.2 Middle East & Africa Injectable HIV Medication Revenue by Country (2021-2026)
8.2 Middle East & Africa Injectable HIV Medication Sales by Type (2021-2026)
8.3 Middle East & Africa Injectable HIV Medication Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Injectable HIV Medication
10.3 Manufacturing Process Analysis of Injectable HIV Medication
10.4 Industry Chain Structure of Injectable HIV Medication
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Injectable HIV Medication Distributors
11.3 Injectable HIV Medication Customer
12 WORLD FORECAST REVIEW FOR INJECTABLE HIV MEDICATION BY GEOGRAPHIC REGION
12.1 Global Injectable HIV Medication Market Size Forecast by Region
12.1.1 Global Injectable HIV Medication Forecast by Region (2027-2032)
12.1.2 Global Injectable HIV Medication Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Injectable HIV Medication Forecast by Type (2027-2032)
12.7 Global Injectable HIV Medication Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ViiV Healthcare
13.1.1 ViiV Healthcare Company Information
13.1.2 ViiV Healthcare Injectable HIV Medication Product Portfolios and Specifications
13.1.3 ViiV Healthcare Injectable HIV Medication Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ViiV Healthcare Main Business Overview
13.1.5 ViiV Healthcare Latest Developments
13.2 Janssen Pharmaceuticals
13.2.1 Janssen Pharmaceuticals Company Information
13.2.2 Janssen Pharmaceuticals Injectable HIV Medication Product Portfolios and Specifications
13.2.3 Janssen Pharmaceuticals Injectable HIV Medication Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Janssen Pharmaceuticals Main Business Overview
13.2.5 Janssen Pharmaceuticals Latest Developments
13.3 Gilead Sciences
13.3.1 Gilead Sciences Company Information
13.3.2 Gilead Sciences Injectable HIV Medication Product Portfolios and Specifications
13.3.3 Gilead Sciences Injectable HIV Medication Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Gilead Sciences Main Business Overview
13.3.5 Gilead Sciences Latest Developments
13.4 Theratechnologies
13.4.1 Theratechnologies Company Information
13.4.2 Theratechnologies Injectable HIV Medication Product Portfolios and Specifications
13.4.3 Theratechnologies Injectable HIV Medication Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Theratechnologies Main Business Overview
13.4.5 Theratechnologies Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Injectable HIV Medication Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Injectable HIV Medication Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of NNRTIs
Table 4. Major Players of Capsid Inhibitors
Table 5. Major Players of Integrase Inhibitors
Table 6. Major Players of Monoclonal Antibodies
Table 7. Major Players of Other
Table 8. Global Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 9. Global Injectable HIV Medication Sales Market Share by Type (2021-2026)
Table 10. Global Injectable HIV Medication Revenue by Type (2021-2026) & ($ million)
Table 11. Global Injectable HIV Medication Revenue Market Share by Type (2021-2026)
Table 12. Global Injectable HIV Medication Sale Price by Type (2021-2026) & (US$/Dose)
Table 13. Major Players of Short-interval Injections
Table 14. Major Players of Monthly Injections
Table 15. Major Players of Quarterly Injections
Table 16. Global Injectable HIV Medication Sales by Dosing Interval (2021-2026) & (K Dose)
Table 17. Global Injectable HIV Medication Sales Market Share by Dosing Interval (2021-2026)
Table 18. Global Injectable HIV Medication Revenue by Dosing Interval (2021-2026) & ($ million)
Table 19. Global Injectable HIV Medication Revenue Market Share by Dosing Interval (2021-2026)
Table 20. Global Injectable HIV Medication Sale Price by Dosing Interval (2021-2026) & (US$/Dose)
Table 21. Major Players of Original Drug
Table 22. Major Players of Generic Drug
Table 23. Global Injectable HIV Medication Sales by Drug Properties (2021-2026) & (K Dose)
Table 24. Global Injectable HIV Medication Sales Market Share by Drug Properties (2021-2026)
Table 25. Global Injectable HIV Medication Revenue by Drug Properties (2021-2026) & ($ million)
Table 26. Global Injectable HIV Medication Revenue Market Share by Drug Properties (2021-2026)
Table 27. Global Injectable HIV Medication Sale Price by Drug Properties (2021-2026) & (US$/Dose)
Table 28. Global Injectable HIV Medication Sale by Application (2021-2026) & (K Dose)
Table 29. Global Injectable HIV Medication Sale Market Share by Application (2021-2026)
Table 30. Global Injectable HIV Medication Revenue by Application (2021-2026) & ($ million)
Table 31. Global Injectable HIV Medication Revenue Market Share by Application (2021-2026)
Table 32. Global Injectable HIV Medication Sale Price by Application (2021-2026) & (US$/Dose)
Table 33. Global Injectable HIV Medication Sales by Company (2021-2026) & (K Dose)
Table 34. Global Injectable HIV Medication Sales Market Share by Company (2021-2026)
Table 35. Global Injectable HIV Medication Revenue by Company (2021-2026) & ($ millions)
Table 36. Global Injectable HIV Medication Revenue Market Share by Company (2021-2026)
Table 37. Global Injectable HIV Medication Sale Price by Company (2021-2026) & (US$/Dose)
Table 38. Key Manufacturers Injectable HIV Medication Producing Area Distribution and Sales Area
Table 39. Players Injectable HIV Medication Products Offered
Table 40. Injectable HIV Medication Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global Injectable HIV Medication Sales by Geographic Region (2021-2026) & (K Dose)
Table 44. Global Injectable HIV Medication Sales Market Share Geographic Region (2021-2026)
Table 45. Global Injectable HIV Medication Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global Injectable HIV Medication Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global Injectable HIV Medication Sales by Country/Region (2021-2026) & (K Dose)
Table 48. Global Injectable HIV Medication Sales Market Share by Country/Region (2021-2026)
Table 49. Global Injectable HIV Medication Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global Injectable HIV Medication Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas Injectable HIV Medication Sales by Country (2021-2026) & (K Dose)
Table 52. Americas Injectable HIV Medication Sales Market Share by Country (2021-2026)
Table 53. Americas Injectable HIV Medication Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 55. Americas Injectable HIV Medication Sales by Application (2021-2026) & (K Dose)
Table 56. APAC Injectable HIV Medication Sales by Region (2021-2026) & (K Dose)
Table 57. APAC Injectable HIV Medication Sales Market Share by Region (2021-2026)
Table 58. APAC Injectable HIV Medication Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 60. APAC Injectable HIV Medication Sales by Application (2021-2026) & (K Dose)
Table 61. Europe Injectable HIV Medication Sales by Country (2021-2026) & (K Dose)
Table 62. Europe Injectable HIV Medication Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 64. Europe Injectable HIV Medication Sales by Application (2021-2026) & (K Dose)
Table 65. Middle East & Africa Injectable HIV Medication Sales by Country (2021-2026) & (K Dose)
Table 66. Middle East & Africa Injectable HIV Medication Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 68. Middle East & Africa Injectable HIV Medication Sales by Application (2021-2026) & (K Dose)
Table 69. Key Market Drivers & Growth Opportunities of Injectable HIV Medication
Table 70. Key Market Challenges & Risks of Injectable HIV Medication
Table 71. Key Industry Trends of Injectable HIV Medication
Table 72. Injectable HIV Medication Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Injectable HIV Medication Distributors List
Table 75. Injectable HIV Medication Customer List
Table 76. Global Injectable HIV Medication Sales Forecast by Region (2027-2032) & (K Dose)
Table 77. Global Injectable HIV Medication Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas Injectable HIV Medication Sales Forecast by Country (2027-2032) & (K Dose)
Table 79. Americas Injectable HIV Medication Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC Injectable HIV Medication Sales Forecast by Region (2027-2032) & (K Dose)
Table 81. APAC Injectable HIV Medication Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe Injectable HIV Medication Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Europe Injectable HIV Medication Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa Injectable HIV Medication Sales Forecast by Country (2027-2032) & (K Dose)
Table 85. Middle East & Africa Injectable HIV Medication Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global Injectable HIV Medication Sales Forecast by Type (2027-2032) & (K Dose)
Table 87. Global Injectable HIV Medication Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global Injectable HIV Medication Sales Forecast by Application (2027-2032) & (K Dose)
Table 89. Global Injectable HIV Medication Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. ViiV Healthcare Basic Information, Injectable HIV Medication Manufacturing Base, Sales Area and Its Competitors
Table 91. ViiV Healthcare Injectable HIV Medication Product Portfolios and Specifications
Table 92. ViiV Healthcare Injectable HIV Medication Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. ViiV Healthcare Main Business
Table 94. ViiV Healthcare Latest Developments
Table 95. Janssen Pharmaceuticals Basic Information, Injectable HIV Medication Manufacturing Base, Sales Area and Its Competitors
Table 96. Janssen Pharmaceuticals Injectable HIV Medication Product Portfolios and Specifications
Table 97. Janssen Pharmaceuticals Injectable HIV Medication Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. Janssen Pharmaceuticals Main Business
Table 99. Janssen Pharmaceuticals Latest Developments
Table 100. Gilead Sciences Basic Information, Injectable HIV Medication Manufacturing Base, Sales Area and Its Competitors
Table 101. Gilead Sciences Injectable HIV Medication Product Portfolios and Specifications
Table 102. Gilead Sciences Injectable HIV Medication Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 103. Gilead Sciences Main Business
Table 104. Gilead Sciences Latest Developments
Table 105. Theratechnologies Basic Information, Injectable HIV Medication Manufacturing Base, Sales Area and Its Competitors
Table 106. Theratechnologies Injectable HIV Medication Product Portfolios and Specifications
Table 107. Theratechnologies Injectable HIV Medication Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. Theratechnologies Main Business
Table 109. Theratechnologies Latest Developments
Table 1. Injectable HIV Medication Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Injectable HIV Medication Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of NNRTIs
Table 4. Major Players of Capsid Inhibitors
Table 5. Major Players of Integrase Inhibitors
Table 6. Major Players of Monoclonal Antibodies
Table 7. Major Players of Other
Table 8. Global Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 9. Global Injectable HIV Medication Sales Market Share by Type (2021-2026)
Table 10. Global Injectable HIV Medication Revenue by Type (2021-2026) & ($ million)
Table 11. Global Injectable HIV Medication Revenue Market Share by Type (2021-2026)
Table 12. Global Injectable HIV Medication Sale Price by Type (2021-2026) & (US$/Dose)
Table 13. Major Players of Short-interval Injections
Table 14. Major Players of Monthly Injections
Table 15. Major Players of Quarterly Injections
Table 16. Global Injectable HIV Medication Sales by Dosing Interval (2021-2026) & (K Dose)
Table 17. Global Injectable HIV Medication Sales Market Share by Dosing Interval (2021-2026)
Table 18. Global Injectable HIV Medication Revenue by Dosing Interval (2021-2026) & ($ million)
Table 19. Global Injectable HIV Medication Revenue Market Share by Dosing Interval (2021-2026)
Table 20. Global Injectable HIV Medication Sale Price by Dosing Interval (2021-2026) & (US$/Dose)
Table 21. Major Players of Original Drug
Table 22. Major Players of Generic Drug
Table 23. Global Injectable HIV Medication Sales by Drug Properties (2021-2026) & (K Dose)
Table 24. Global Injectable HIV Medication Sales Market Share by Drug Properties (2021-2026)
Table 25. Global Injectable HIV Medication Revenue by Drug Properties (2021-2026) & ($ million)
Table 26. Global Injectable HIV Medication Revenue Market Share by Drug Properties (2021-2026)
Table 27. Global Injectable HIV Medication Sale Price by Drug Properties (2021-2026) & (US$/Dose)
Table 28. Global Injectable HIV Medication Sale by Application (2021-2026) & (K Dose)
Table 29. Global Injectable HIV Medication Sale Market Share by Application (2021-2026)
Table 30. Global Injectable HIV Medication Revenue by Application (2021-2026) & ($ million)
Table 31. Global Injectable HIV Medication Revenue Market Share by Application (2021-2026)
Table 32. Global Injectable HIV Medication Sale Price by Application (2021-2026) & (US$/Dose)
Table 33. Global Injectable HIV Medication Sales by Company (2021-2026) & (K Dose)
Table 34. Global Injectable HIV Medication Sales Market Share by Company (2021-2026)
Table 35. Global Injectable HIV Medication Revenue by Company (2021-2026) & ($ millions)
Table 36. Global Injectable HIV Medication Revenue Market Share by Company (2021-2026)
Table 37. Global Injectable HIV Medication Sale Price by Company (2021-2026) & (US$/Dose)
Table 38. Key Manufacturers Injectable HIV Medication Producing Area Distribution and Sales Area
Table 39. Players Injectable HIV Medication Products Offered
Table 40. Injectable HIV Medication Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global Injectable HIV Medication Sales by Geographic Region (2021-2026) & (K Dose)
Table 44. Global Injectable HIV Medication Sales Market Share Geographic Region (2021-2026)
Table 45. Global Injectable HIV Medication Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global Injectable HIV Medication Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global Injectable HIV Medication Sales by Country/Region (2021-2026) & (K Dose)
Table 48. Global Injectable HIV Medication Sales Market Share by Country/Region (2021-2026)
Table 49. Global Injectable HIV Medication Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global Injectable HIV Medication Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas Injectable HIV Medication Sales by Country (2021-2026) & (K Dose)
Table 52. Americas Injectable HIV Medication Sales Market Share by Country (2021-2026)
Table 53. Americas Injectable HIV Medication Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 55. Americas Injectable HIV Medication Sales by Application (2021-2026) & (K Dose)
Table 56. APAC Injectable HIV Medication Sales by Region (2021-2026) & (K Dose)
Table 57. APAC Injectable HIV Medication Sales Market Share by Region (2021-2026)
Table 58. APAC Injectable HIV Medication Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 60. APAC Injectable HIV Medication Sales by Application (2021-2026) & (K Dose)
Table 61. Europe Injectable HIV Medication Sales by Country (2021-2026) & (K Dose)
Table 62. Europe Injectable HIV Medication Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 64. Europe Injectable HIV Medication Sales by Application (2021-2026) & (K Dose)
Table 65. Middle East & Africa Injectable HIV Medication Sales by Country (2021-2026) & (K Dose)
Table 66. Middle East & Africa Injectable HIV Medication Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa Injectable HIV Medication Sales by Type (2021-2026) & (K Dose)
Table 68. Middle East & Africa Injectable HIV Medication Sales by Application (2021-2026) & (K Dose)
Table 69. Key Market Drivers & Growth Opportunities of Injectable HIV Medication
Table 70. Key Market Challenges & Risks of Injectable HIV Medication
Table 71. Key Industry Trends of Injectable HIV Medication
Table 72. Injectable HIV Medication Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Injectable HIV Medication Distributors List
Table 75. Injectable HIV Medication Customer List
Table 76. Global Injectable HIV Medication Sales Forecast by Region (2027-2032) & (K Dose)
Table 77. Global Injectable HIV Medication Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas Injectable HIV Medication Sales Forecast by Country (2027-2032) & (K Dose)
Table 79. Americas Injectable HIV Medication Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC Injectable HIV Medication Sales Forecast by Region (2027-2032) & (K Dose)
Table 81. APAC Injectable HIV Medication Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe Injectable HIV Medication Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Europe Injectable HIV Medication Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa Injectable HIV Medication Sales Forecast by Country (2027-2032) & (K Dose)
Table 85. Middle East & Africa Injectable HIV Medication Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global Injectable HIV Medication Sales Forecast by Type (2027-2032) & (K Dose)
Table 87. Global Injectable HIV Medication Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global Injectable HIV Medication Sales Forecast by Application (2027-2032) & (K Dose)
Table 89. Global Injectable HIV Medication Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. ViiV Healthcare Basic Information, Injectable HIV Medication Manufacturing Base, Sales Area and Its Competitors
Table 91. ViiV Healthcare Injectable HIV Medication Product Portfolios and Specifications
Table 92. ViiV Healthcare Injectable HIV Medication Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. ViiV Healthcare Main Business
Table 94. ViiV Healthcare Latest Developments
Table 95. Janssen Pharmaceuticals Basic Information, Injectable HIV Medication Manufacturing Base, Sales Area and Its Competitors
Table 96. Janssen Pharmaceuticals Injectable HIV Medication Product Portfolios and Specifications
Table 97. Janssen Pharmaceuticals Injectable HIV Medication Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. Janssen Pharmaceuticals Main Business
Table 99. Janssen Pharmaceuticals Latest Developments
Table 100. Gilead Sciences Basic Information, Injectable HIV Medication Manufacturing Base, Sales Area and Its Competitors
Table 101. Gilead Sciences Injectable HIV Medication Product Portfolios and Specifications
Table 102. Gilead Sciences Injectable HIV Medication Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 103. Gilead Sciences Main Business
Table 104. Gilead Sciences Latest Developments
Table 105. Theratechnologies Basic Information, Injectable HIV Medication Manufacturing Base, Sales Area and Its Competitors
Table 106. Theratechnologies Injectable HIV Medication Product Portfolios and Specifications
Table 107. Theratechnologies Injectable HIV Medication Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. Theratechnologies Main Business
Table 109. Theratechnologies Latest Developments
LIST OF FIGURES
Figure 1. Picture of Injectable HIV Medication
Figure 2. Injectable HIV Medication Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Injectable HIV Medication Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Injectable HIV Medication Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Injectable HIV Medication Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Injectable HIV Medication Sales Market Share by Country/Region (2025)
Figure 10. Injectable HIV Medication Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of NNRTIs
Figure 12. Product Picture of Capsid Inhibitors
Figure 13. Product Picture of Integrase Inhibitors
Figure 14. Product Picture of Monoclonal Antibodies
Figure 15. Product Picture of Other
Figure 16. Global Injectable HIV Medication Sales Market Share by Type in 2026
Figure 17. Global Injectable HIV Medication Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Short-interval Injections
Figure 19. Product Picture of Monthly Injections
Figure 20. Product Picture of Quarterly Injections
Figure 21. Global Injectable HIV Medication Sales Market Share by Dosing Interval in 2026
Figure 22. Global Injectable HIV Medication Revenue Market Share by Dosing Interval (2021-2026)
Figure 23. Product Picture of Original Drug
Figure 24. Product Picture of Generic Drug
Figure 25. Global Injectable HIV Medication Sales Market Share by Drug Properties in 2026
Figure 26. Global Injectable HIV Medication Revenue Market Share by Drug Properties (2021-2026)
Figure 27. Injectable HIV Medication Consumed in Pre-Exposure Prophylaxis
Figure 28. Global Injectable HIV Medication Market: Pre-Exposure Prophylaxis (2021-2026) & (K Dose)
Figure 29. Injectable HIV Medication Consumed in HIV Treatment
Figure 30. Global Injectable HIV Medication Market: HIV Treatment (2021-2026) & (K Dose)
Figure 31. Global Injectable HIV Medication Sale Market Share by Application (2025)
Figure 32. Global Injectable HIV Medication Revenue Market Share by Application in 2025
Figure 33. Injectable HIV Medication Sales by Company in 2025 (K Dose)
Figure 34. Global Injectable HIV Medication Sales Market Share by Company in 2025
Figure 35. Injectable HIV Medication Revenue by Company in 2025 ($ millions)
Figure 36. Global Injectable HIV Medication Revenue Market Share by Company in 2025
Figure 37. Global Injectable HIV Medication Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Injectable HIV Medication Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Injectable HIV Medication Sales 2021-2026 (K Dose)
Figure 40. Americas Injectable HIV Medication Revenue 2021-2026 ($ millions)
Figure 41. APAC Injectable HIV Medication Sales 2021-2026 (K Dose)
Figure 42. APAC Injectable HIV Medication Revenue 2021-2026 ($ millions)
Figure 43. Europe Injectable HIV Medication Sales 2021-2026 (K Dose)
Figure 44. Europe Injectable HIV Medication Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Injectable HIV Medication Sales 2021-2026 (K Dose)
Figure 46. Middle East & Africa Injectable HIV Medication Revenue 2021-2026 ($ millions)
Figure 47. Americas Injectable HIV Medication Sales Market Share by Country in 2025
Figure 48. Americas Injectable HIV Medication Revenue Market Share by Country (2021-2026)
Figure 49. Americas Injectable HIV Medication Sales Market Share by Type (2021-2026)
Figure 50. Americas Injectable HIV Medication Sales Market Share by Application (2021-2026)
Figure 51. United States Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Injectable HIV Medication Sales Market Share by Region in 2025
Figure 56. APAC Injectable HIV Medication Revenue Market Share by Region (2021-2026)
Figure 57. APAC Injectable HIV Medication Sales Market Share by Type (2021-2026)
Figure 58. APAC Injectable HIV Medication Sales Market Share by Application (2021-2026)
Figure 59. China Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 63. India Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Injectable HIV Medication Sales Market Share by Country in 2025
Figure 67. Europe Injectable HIV Medication Revenue Market Share by Country (2021-2026)
Figure 68. Europe Injectable HIV Medication Sales Market Share by Type (2021-2026)
Figure 69. Europe Injectable HIV Medication Sales Market Share by Application (2021-2026)
Figure 70. Germany Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 71. France Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Injectable HIV Medication Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Injectable HIV Medication Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Injectable HIV Medication Sales Market Share by Application (2021-2026)
Figure 78. Egypt Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Injectable HIV Medication in 2026
Figure 84. Manufacturing Process Analysis of Injectable HIV Medication
Figure 85. Industry Chain Structure of Injectable HIV Medication
Figure 86. Channels of Distribution
Figure 87. Global Injectable HIV Medication Sales Market Forecast by Region (2027-2032)
Figure 88. Global Injectable HIV Medication Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Injectable HIV Medication Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Injectable HIV Medication Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Injectable HIV Medication Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Injectable HIV Medication Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Injectable HIV Medication
Figure 2. Injectable HIV Medication Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Injectable HIV Medication Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Injectable HIV Medication Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Injectable HIV Medication Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Injectable HIV Medication Sales Market Share by Country/Region (2025)
Figure 10. Injectable HIV Medication Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of NNRTIs
Figure 12. Product Picture of Capsid Inhibitors
Figure 13. Product Picture of Integrase Inhibitors
Figure 14. Product Picture of Monoclonal Antibodies
Figure 15. Product Picture of Other
Figure 16. Global Injectable HIV Medication Sales Market Share by Type in 2026
Figure 17. Global Injectable HIV Medication Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Short-interval Injections
Figure 19. Product Picture of Monthly Injections
Figure 20. Product Picture of Quarterly Injections
Figure 21. Global Injectable HIV Medication Sales Market Share by Dosing Interval in 2026
Figure 22. Global Injectable HIV Medication Revenue Market Share by Dosing Interval (2021-2026)
Figure 23. Product Picture of Original Drug
Figure 24. Product Picture of Generic Drug
Figure 25. Global Injectable HIV Medication Sales Market Share by Drug Properties in 2026
Figure 26. Global Injectable HIV Medication Revenue Market Share by Drug Properties (2021-2026)
Figure 27. Injectable HIV Medication Consumed in Pre-Exposure Prophylaxis
Figure 28. Global Injectable HIV Medication Market: Pre-Exposure Prophylaxis (2021-2026) & (K Dose)
Figure 29. Injectable HIV Medication Consumed in HIV Treatment
Figure 30. Global Injectable HIV Medication Market: HIV Treatment (2021-2026) & (K Dose)
Figure 31. Global Injectable HIV Medication Sale Market Share by Application (2025)
Figure 32. Global Injectable HIV Medication Revenue Market Share by Application in 2025
Figure 33. Injectable HIV Medication Sales by Company in 2025 (K Dose)
Figure 34. Global Injectable HIV Medication Sales Market Share by Company in 2025
Figure 35. Injectable HIV Medication Revenue by Company in 2025 ($ millions)
Figure 36. Global Injectable HIV Medication Revenue Market Share by Company in 2025
Figure 37. Global Injectable HIV Medication Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Injectable HIV Medication Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Injectable HIV Medication Sales 2021-2026 (K Dose)
Figure 40. Americas Injectable HIV Medication Revenue 2021-2026 ($ millions)
Figure 41. APAC Injectable HIV Medication Sales 2021-2026 (K Dose)
Figure 42. APAC Injectable HIV Medication Revenue 2021-2026 ($ millions)
Figure 43. Europe Injectable HIV Medication Sales 2021-2026 (K Dose)
Figure 44. Europe Injectable HIV Medication Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Injectable HIV Medication Sales 2021-2026 (K Dose)
Figure 46. Middle East & Africa Injectable HIV Medication Revenue 2021-2026 ($ millions)
Figure 47. Americas Injectable HIV Medication Sales Market Share by Country in 2025
Figure 48. Americas Injectable HIV Medication Revenue Market Share by Country (2021-2026)
Figure 49. Americas Injectable HIV Medication Sales Market Share by Type (2021-2026)
Figure 50. Americas Injectable HIV Medication Sales Market Share by Application (2021-2026)
Figure 51. United States Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Injectable HIV Medication Sales Market Share by Region in 2025
Figure 56. APAC Injectable HIV Medication Revenue Market Share by Region (2021-2026)
Figure 57. APAC Injectable HIV Medication Sales Market Share by Type (2021-2026)
Figure 58. APAC Injectable HIV Medication Sales Market Share by Application (2021-2026)
Figure 59. China Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 63. India Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Injectable HIV Medication Sales Market Share by Country in 2025
Figure 67. Europe Injectable HIV Medication Revenue Market Share by Country (2021-2026)
Figure 68. Europe Injectable HIV Medication Sales Market Share by Type (2021-2026)
Figure 69. Europe Injectable HIV Medication Sales Market Share by Application (2021-2026)
Figure 70. Germany Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 71. France Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Injectable HIV Medication Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Injectable HIV Medication Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Injectable HIV Medication Sales Market Share by Application (2021-2026)
Figure 78. Egypt Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Injectable HIV Medication Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Injectable HIV Medication in 2026
Figure 84. Manufacturing Process Analysis of Injectable HIV Medication
Figure 85. Industry Chain Structure of Injectable HIV Medication
Figure 86. Channels of Distribution
Figure 87. Global Injectable HIV Medication Sales Market Forecast by Region (2027-2032)
Figure 88. Global Injectable HIV Medication Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Injectable HIV Medication Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Injectable HIV Medication Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Injectable HIV Medication Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Injectable HIV Medication Revenue Market Share Forecast by Application (2027-2032)
